Voyager closes Neurocrine collaboration, receives $175M; Neurocrine CSO joins board

Voyager Therapeutics, Inc.

Collaboration Agreement effective; Neurocrine pays $136M upfront.
Neurocrine buys 4,395,588 shares at $8.88/share for ~$39M.
Jude Onyia, Ph.D., Neurocrine's CSO, appointed to board effective closing.
Onyia designated Class III director until 2024 annual meeting; Neurocrine retains nomination right while holding ≥10%.
Onyia receives standard non-employee director compensation: $40K cash retainer, initial option for 44,000 shares, annual option for 22,000 shares.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jude Onyia, Ph.D.

director

VYGR · Voyager Therapeutics, Inc.

Effective: 2023-02-23
Filed: February 24, 2023, 6:59 PM ET

the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jude Onyia, Ph.D. was appointed as director at Voyager Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”), approved the appointment of Jude Onyia, Ph.D., to serve as a director of the Company, contingent upon and effective as of the closing

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-024939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.